2020
Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease
Mirelman A, Hillel I, Rochester L, Del Din S, Bloem BR, Avanzino L, Nieuwboer A, Maidan I, Herman T, Thaler A, Gurevich T, Kestenbaum M, Orr‐Urtreger A, Brys M, Cedarbaum JM, Giladi N, Hausdorff JM. Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. Movement Disorders 2020, 35: 959-968. PMID: 32080891, DOI: 10.1002/mds.28006.Peer-Reviewed Original ResearchConceptsAdvanced Parkinson's diseaseParkinson's diseaseNocturnal hypokinesiaDopaminergic medicationSleep disturbancesDisease severityDiverse disease severitiesPD motor severityUpright periodsDopaminergic treatmentNonmotor symptomsUpright timeMotor severityHealthy controlsSleep interruptionDisease spectrumPatientsSeverityMedicationsHypokinesiaDiseaseNocturnal movementsDegree of rotationTri-axial accelerometerDysautonomia
1993
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt JG. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993, 43: 1704-8. PMID: 8414016, DOI: 10.1212/wnl.43.9.1704.Peer-Reviewed Original ResearchConceptsL-DOPAMotor responseLarge neutral amino acidsVentricular CSF concentrationsAdvanced Parkinson's diseaseL-DOPA infusionL-DOPA levelsClinical responseParkinsonian patientsCSF concentrationsOral administrationNeutral amino acidsParkinson's diseaseInfusionPatientsPhenylalanine challengeReliable predictorCSFVDiseaseBrainDurationResponsePlasmaLevelsAdministration
1992
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
Guttman M, Léger G, Cedarbaum J, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals Of Neurology 1992, 31: 638-643. PMID: 1514775, DOI: 10.1002/ana.410310611.Peer-Reviewed Original ResearchConceptsChronic L-DOPA therapyAdvanced Parkinson's diseaseL-dopa therapyPositron emission tomographic studiesL-DOPA administrationEmission tomographic studiesPositron emission tomographyL-dopa preparationsParkinsonian patientsPlasma concentrationsCynomolgus monkeysParkinson's diseasePatientsEmission tomographyL-DOPABrainTomographic studiesDiseaseAdministrationInfusionTherapyBlood
1991
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Cedarbaum J, Olanow CW. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease. Neurology 1991, 41: 1567-70. PMID: 1922797, DOI: 10.1212/wnl.41.10.1567.Peer-Reviewed Original ResearchConceptsAdvanced Parkinson's diseaseDopamine sulfateParkinson's diseaseDopamine sulfate levelsLevodopa/carbidopaTime of transplantationPeak plasma concentrationAvailability of dopamineVentricular cerebrospinal fluidSulfate levelsClinical improvementMotor fluctuationsOmmaya reservoirSingle doseExogenous levodopaParkinsonian brainMotor functionPlasma concentrationsLateral ventricleCerebrospinal fluidAdrenal medullaLevodopaPatientsDiseaseDopamineL-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations.
Cedarbaum JM, Toy LH, Green-Parsons A. L-Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations. Clinical Neuropharmacology 1991, 14: 228. PMID: 1906374, DOI: 10.1097/00002826-199106000-00005.Peer-Reviewed Original ResearchConceptsSinemet CRParkinson's diseaseResponse fluctuationsDisease patientsL-deprenylMean interdose intervalTherapeutic response fluctuationsAdvanced Parkinson's diseaseMotor response fluctuationsParkinson's disease patientsLevodopa intakeMotor fluctuationsInterdose intervalTreatment regimensPatientsSignificant reductionDeprenylDiseaseRegimensDyskinesiaImproved controlTemporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease
Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Annals Of Neurology 1991, 29: 556-559. PMID: 1859185, DOI: 10.1002/ana.410290516.Peer-Reviewed Original ResearchConceptsVentricular cerebrospinal fluidCerebrospinal fluidParkinson's diseasePlasma levodopa concentrationsAdvanced Parkinson's diseaseCerebrospinal fluid pharmacokineticsPharmacokinetics of levodopaCentral nervous systemLevodopa levelsOmmaya reservoirClinical effectsLevodopa effectsParkinsonian patientsLevodopa concentrationsHomovanillic acidNervous systemDrug concentrationsLevodopaDiseaseMotor performancePatientsTime coursePharmacokineticsTemporal relationshipNucleus transplantation
1989
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM, Kutt H, McDowell FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989, 39: 38-44; discussion 59. PMID: 2586762.Peer-Reviewed Original ResearchConceptsSinemet CRLevodopa levelsNew controlled-release formulationStandard Sinemet 25/100Advanced Parkinson's diseasePlasma levodopa levelsBioavailability of levodopaClinical observation studyAntiparkinsonian effectsLevodopa intakeSinemet 25/100Standard SinemetPharmacodynamic comparisonMedication dosesInterdose intervalParkinson's diseaseCR preparationControlled-release formulationLevodopaMotor performanceCarbidopaObservation studyDiseaseProlongationSinemet
1988
Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease.
Cedarbaum JM, Hoey M, Kutt H, McDowell FH. Controlled-Release Levodopa/Carbidopa III: Sinemet CR5 Treatment of Response Fluctuations in Parkinson's Disease. Clinical Neuropharmacology 1988, 11: 168. PMID: 3378225, DOI: 10.1097/00002826-198804000-00008.Peer-Reviewed Original ResearchConceptsSinemet CR4Parkinson's diseasePeak plasma levodopa concentrationResponse fluctuationsOpen-label studyAdvanced Parkinson's diseasePlasma levodopa concentrationsStandard SinemetInterdose intervalDaily dosesTherapeutic responseLevodopa concentrationsSame patientLabel studyDiseaseRelative bioavailabilityPatientsGreater delayTreatmentSinemetLevodopaDoses